The incidence of severe thrombotic events , which was relatively low was similar regardless of the treatment, and there were no grade 5 thrombotic events among patients treated with the combination of both targeted therapies.
The significant risk factors for VTEs identified in this study were being age 60 years or older, having a score of 1 on the ECOG Performance Status Scale, and response to treatment . At a press conference organized by the Institut Curie before the ASCO conference, Girard said,"There has been shown to be an increased risk of blood clots with the use of this combination of targeted therapies. Preventive measures should therefore also be put forward, such as adding anticoagulant medication. This is an important study for the further development of these therapies."
In a press release, the respiratory medicine specialist noted,"Institut Curie is particularly alert to the issue of the risk of thrombosis arising in cancer patients.
Girard has direct links with Amgen, AstraZeneca, AbbVie, BMS, Daiichi Sankyo, Ipsen, Janssen, Roche, Lilly, Medtronic, MSD, Novartis, OSE Pharma, Pfizer, Sanofi, and Sivan.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
HCA Kingwood's $28 million expansion underway as surgical patients increaseHCA Houston Healthcare Kingwood is embarking on a $28 million expansion of the...
Source: HoustonChron - 🏆 609. / 51 Read more »